How Analysts Feel About Aurinia Pharmaceuticals Inc. (AUPH)?

As of Friday close, Aurinia Pharmaceuticals Inc.’s (NASDAQ:AUPH) stock was up $1.28, moving up 12.94 percent to $11.17. The average number of shares traded per day over the past five days has been 4,108,800 shares. 3 times new highs have been achieved over the past 5 days, with a $1.01 gain in that time frame. In the last twenty days, the average volume was 2,420,525, while in the previous 50 days, it was 2,315,462.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


Since last month, AUPH stock retreated -9.04%. Shares of the company fell to $8.86 on 05/09/22, the lowest level in the past month. A 52-week high of $33.97 was reached on 01/03/22 after having rallying from a 52-week low of $8.86. Since the beginning of this year, AUPH’s stock price has dropped by -51.16% or -$11.70, and marked a new high 1 time. However, the stock has declined by -67.12% since its 52-week high.

Aurinia Pharmaceuticals Inc. (AUPH) last reported insider trading activity 66 days ago on Mar 09. MacKay-Dunn R. Hector, the Director of the company, purchased of 5,000 shares for $11.00 on Mar 09. It resulted in a $54,985 investment by the insider. MILNE GEORGE M JR added 5,000 shares at an average price of $10.82 on Mar 04. The insider now owns 50,000 shares following the transaction. On Mar 02, Ex VP, Intern’l Operations Donley Matthew Maxwell sold 3,052 shares at $12.01 apiece. The transaction was valued at $36,655.

Valuation Metrics

The stock’s beta is 1.09. Besides these, the trailing price-to-sales (P/S) ratio of 37.08, the price-to-book (PB) ratio of 3.10.

Financial Health

In the three months ended September 29, Aurinia Pharmaceuticals Inc.’s quick ratio stood at 12.20, while its current ratio was 12.60, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 97.60% percent. Based on annual data, AUPH earned $44.51 million in gross profit and brought in $45.6 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -37.90%. Return on equity (ROE) for the past 12 months was -48.90%.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. AUPH’s revenue rose 95.79% to $23.4 million during the quarter, while net income inched up to $21.63 million. While analysts expected Aurinia Pharmaceuticals Inc. to report -$0.33 quarterly earnings, the actual figure was -$0.39 per share, beating the consensus estimate by -18.20%. During the quarter, the company generated -$35.76 million in EBITDA. The liabilities of Aurinia Pharmaceuticals Inc. were 58.78 million at the end of its most recent quarter ended September 29, and its total debt was $8.91 million.

Technical Picture

This quick technical analysis looks at Aurinia Pharmaceuticals Inc.’s (AUPH) price momentum. With a historical volatility rate of 182.67%, the RSI 9-day stood at 53.65% on 13 May.

With respect to its five-day moving average, the current Aurinia Pharmaceuticals Inc. price is up by +9.94% percent or $1.01. At present, AUPH shares trade -5.74% below its 20-day simple moving average and -46.96% percent below its 100-day simple moving average. However, the stock is currently trading approximately +2.57% above its SMA50 and -19.93% below its SMA200.

Stochastic coefficient K was 51.73% and Stochastic coefficient D was 45.36%, while ATR was 1.07. Given the Stochastic reading of 91.31% for the 14-day period, the RSI (14) reading has been calculated as 50.81%. As of today, the MACD Oscillator reading stands at -0.27, while the 14-day reading stands at -0.34.

Analyst Ratings

Aurinia Pharmaceuticals Inc. (AUPH) has been rated Buy by analysts. According to 0 brokerage firms, AUPH is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Aurinia Pharmaceuticals Inc. stock as buy, with 8 recommending it as overweight.

With a median target price of $23.50, the current consensus forecast for the stock is $15.00 – $30.00. Based on these forecasts, analysts predict Aurinia Pharmaceuticals Inc. (AUPH) will achieve an average price target of $23.81.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles